Evidence map›Paper›PMID 39284532›Full record

ArticleInternational journal of radiation oncology, biology, physics2025

Using Integrin α

William C Y Lo, Cristian W Villas Boas, Truc T Huynh, Amanda Klaas, Felicia Grogan, Lori Strong, Pamela Samson, Clifford G Robinson, Buck E Rogers, Carmen Bergom

Abstract read
In one paragraph

Article in International journal of radiation oncology, biology, physics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

William C Y LoDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.
Cristian W Villas BoasDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.
Truc T HuynhDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri; Department of Chemistry, Washington University in St Louis, St Louis, Missouri.
Amanda KlaasDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.
Felicia GroganDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.
Lori StrongDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.
Pamela SamsonDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.
Clifford G RobinsonDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.
Buck E RogersDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri. Electronic address: b.rogers@wustl.edu.
Carmen BergomDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri. Electronic address: cbergom@wustl.edu.

Funding

Washington University Institute of Clinical and Translational SciencesUL1TR000448 · NCATS · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2012 to 2016
$41.4M
Washington University (WU) ROBIN Center: MicroEnvironment and Tumor Effects Of Radiotherapy (METEOR)U54CA274318 · NCI · WASHINGTON UNIVERSITY · PI Clifford Grant Robinson · 2023 to 2026
$7.7M
Genetic Modifiers of Radiation Therapy-Induced CardiotoxicityR01HL147884 · NHLBI · WASHINGTON UNIVERSITY · PI BERGOM, CARMEN · 2019 to 2023
$2.3M
PURCHASE OF AN IMAGE-GUIDED SMALL-ANIMAL IRRADIATORS10OD020136 · OD · WASHINGTON UNIVERSITY · PI HALLAHAN, DENNIS E · 2015 to 2015
$600k
NCATS NIH HHS UL1 TR000448NCI NIH HHS U54 CA274318NHLBI NIH HHS R01 HL147884NIH HHS S10 OD020136
6 · The paper itself

Abstract

purposeRadiation-induced pulmonary fibrosis (RIPF) is a potentially serious and disabling late complication of radiation therapy. Monitoring RIPF progression is challenging due to the absence of early detection tools and the difficulty in distinguishing RIPF from other lung diseases using standard imaging methods. In the lungs, integrin αvβ6 is crucial in the development of RIPF, acting as a significant activator of transforming growth factor β after radiation injury. This study aimed to investigate integrin α METHODS AND MATERIALS: We used a focal RIPF model (70 Gy delivered focally to a 3 mm spot in the lung) and a whole lung RIPF model (14 Gy delivered to the whole lung) in adult C57BL/6J mice. Small animal PET/computed tomography images were acquired 1 hour postinjection of 11.1 MBq of [

resultsIn the focal RIPF model, there was focal uptake of [

conclusionsIntegrin α

Indexed as

Antigens, NeoplasmIntegrinsPositron-Emission TomographyPositron Emission Tomography Computed TomographyPulmonary FibrosisRadiation PneumonitisAnimalsCopper RadioisotopesLungMiceMice, Inbred C57BLAntigens, NeoplasmCopper Radioisotopesintegrin alphavbeta6Integrins

Identifiers

PMID39284532
PMCPMC12232630

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.